EUCTR2016-000592-24-PL进行中（未招募）1 期
A Randomized, Double-Blind, Multicenter, Placebo- and active Comparator-Controlled Study to evaluate Efficacy and Safety of MR308 in the Treatment of Acute Pain After Third Molar Tooth Extraction (STARDOM1). - STARDOM1
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 765
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Only subjects meeting all of the following inclusion criteria will be considered for study inclusion:
- •1. Male/female subjects = 18 years on the day of consent.
- •2. Willing and able to provide written informed consent for this study.
- •3. Subjects must have a planned elective dental procedure i.e. extraction of at least two impacted third molars (one of them must be mandibular) requiring bone removal, within 28 days after the Screening Visit. If only two impacted third molars are extracted, they must be ipsilateral and require bone removal.
- •4. If a female is of child-bearing potential, she must be using highly effective methods of contraception throughout the study, not breastfeeding, and have negative pregnancy tests prior to receiving IMP. A highly effective method of birth control is defined as one which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (Intrauterine Device, hormonal), sexual abstinence or vasectomised partner).
- •5. Good general health as judged by Investigators on the basis of medical history and physical examination.
- •6. Willingness to comply with the study procedures and requirements.
- •Additional Inclusion Criteria after Surgery:
- •1. Third molar extractions completed without any immediate complication.
- •2. Tolerating oral fluids, no uncontrolled nausea/vomiting and ready to take oral analgesia.
- •3. The subject is alert and calm, spontaneously pays attention to caregiver, e.g. RASS = 0 (Sessler et al., 2002 & Ely et al., 2003).
- •4. Subjects with moderate or severe pain (qualifying PI-VAS score = 45mm and
- •< 70mm or = 70mm) as a result of an oral surgical procedure under local anaesthesia and/or sedation*. This must be measured within a maximum of 6 hours after the end of the surgical procedure.
- •* Randomisation within one pain group may be temporarily closed, please see section 11.4 for further details.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 765
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Subjects having any of the following criteria must not be included in the study.
- •1. Any abnormal laboratory value that is clinically significant in the opinion of Investigator that would compromise the safety of the subject in the study.
- •2. Any recent history of frequent nausea or vomiting, dizziness within the last 3 months regardless of etiology.
- •3. Subjects having any medical condition or treatment that is either a warning or contraindication as per the SmPC of tramadol (e.g. selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, MAO inhibitors (within 14 days before taking IMP), antipsychotics, anticonvulsant and other seizure threshold-lowering medicinal products),, celecoxib (e.g. increased risk of post-operative bleeding, active peptic ulceration, GI bleeding or inflammatory bowel disease) or paracetamol.
- •4. Known sensitivity and/or contraindication to tramadol, celecoxib, paracetamol, sulfonamides, opioids, NSAIDS, COX-2 inhibitors, or related compounds or formulation excipients as well as severe hypersensitivity reactions (e.g. angioedema) to any drugs.
- •5. Subjects who are known to have had inadequate pain relief from paracetamol, tramadol or celecoxib.
- •6. Subjects requiring any medication which is prohibited as per section prohibited medication.
- •7. Subjects who are in the Investigators opinion considered at increased risk of post-operative complications e.g. major dental infection/abscess.
- •8. Any history of drug or alcohol abuse, misuse, physical or psychological dependence, mood changes, sleep disturbance and functional capacity which have an impact on pain perception.
- •9. Significant neurological or psychiatric disorders including mental instability (unrelated to the pain) that could interfere with pain assessment; other pain that might impair the assessment of the nociceptive pain.
- •10. Any medical history of significant and/or inadequately controlled cardiovascular (uncontrolled high blood pressure, high risk of cardiovascular events, severe heart failure), pulmonary, hematologic, (including coagulopathy/bleeding disorders), neurological (e.g. subjects with epilepsy or those susceptible to seizures), , liver disease (e.g. severe hepatic impairment), kidney disease (e.g. impaired renal function in subjects taking diuretics, ACE-inhibitors, or angiotensin II antagonists), endocrine, immunologic, dermatologic painful conditions or any other conditions that may compromise the ability of the subject to participate in the study or might interfere with drug absorption, distribution, metabolism or excretion.
- •11. Previous randomisation in this study.
- •12. Subjects who participated in a clinical research study involving a new chemical entity or an experimental drug within 30 days of study entry (defined as the start of the Screening Period).
- •13. Subjects who were treated regularly with opioid analgesic or NSAIDs within 30 days prior to screening or who have received a long-acting NSAID within three days prior to the start of the surgery.
- •14. Subjects who have received any analgesic medication (e.g. NSAIDs, oral opioid preparations etc.) other than short-acting preoperative or intraoperative local anaesthetic agents within 12 hours before the start of the surgery or peri operatively until randomisation.
- •15. Subjects who are incapable of complying with the protocol.
- •Additional Exclusion Criteria after Surgery:
- •1. Serious complication during surgery and up to
研究者
相似试验
进行中（未招募）
1 期
Efficacy and Safety in a randomised acute pain study of MR308.Acute pain after third molar tooth extractiondental procedure must have involved extraction of at least two impacted third molars requireing bone removal. If only two impacted third molars are extracted, they must be ipsilateral and both required bone removal under local anaesthesia.MedDRA version: 20.0 Level: LLT Classification code 10066714 Term: Acute pain System Organ Class: 100000023314EUCTR2016-000592-24-DEMundipharma Research GmbH & Co. KG726
进行中（未招募）
1 期
Efficacy and Safety in a randomised acute pain study of MR308.Acute pain after open total or subtotal abdominal hysterectomyMedDRA version: 19.0Level: LLTClassification code 10066714Term: Acute painSystem Organ Class: 100000004867EUCTR2016-000593-38-ESMundipharma Research GmbH & Co. KG1,100
进行中（未招募）
1 期
Efficacy and Safety in a randomised acute pain study of MR308.Acute pain after open total or subtotal abdominal hysterectomyMedDRA version: 20.1 Level: LLT Classification code 10066714 Term: Acute pain System Organ Class: 100000004867EUCTR2016-000593-38-BGMundipharma Research GmbH & Co. KG1,138
进行中（未招募）
1 期
Efficacy and Safety in a randomised acute pain study of MR308.Acute pain after open total or subtotal abdominal hysterectomyMedDRA version: 20.1Level: LLTClassification code 10066714Term: Acute painSystem Organ Class: 100000004867EUCTR2016-000593-38-SKMundipharma Research GmbH & Co. KG1,100
进行中（未招募）
1 期
Efficacy and Safety in a randomised acute pain study of MR308:STARDOM1.EUCTR2016-000592-24-ITMUNDIPHARMA RESEARCH GMBH & CO. KG765